+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Double-blind randomized controlled pilot study of the efficacy and tolerability of pirlindole, a reversible inhibitor of monoamine oxidase A, and mianserin, in the treatment of depression



Double-blind randomized controlled pilot study of the efficacy and tolerability of pirlindole, a reversible inhibitor of monoamine oxidase A, and mianserin, in the treatment of depression



Human Psychopharmacology. 12(1): 41-46



This double-blind randomized pilot study aimed to compare the efficacy and the tolerability of pirlindole (150-225 mg/day), a reversible inhibitor of monoamine oxidase A, and mianserin (60-90 mg/day) in the treatment of major depression. Forty patients were included in the trial (20 pirlindole and 20 mianserin) and 38 patients (18 pirlindole and 20 mianserin) completed the whole study (28 days of administration). Both treatments exhibited highly significant improvements in the Hamilton Depression Rating Scale score (HDRS), the Hamilton Anxiety Rating Scale score (HARS) and the Beck auto-evaluation scale score (BECK) from day 7 up to day 28. The evolution of the HDRS score in the two groups did not differ significantly. The evolution of the HARS and BECK scores taken separately and the evolution of the combined total score (HDRS + HARS + BECK) significantly differed between the two groups, pirlindole producing a significantly higher decrease than mianserin in the two separate scores on day 28 and on days 21 and 28 in the case of the combined total score. Two patients experienced adverse reactions, one in the pirlindole group complained of sleep disturbances and one in the mianserin group suffered from dry mouth. The results of this study attest to the efficacy and tolerability of pirlindole in the treatment of depression.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 008502203

Download citation: RISBibTeXText

DOI: 10.1002/(sici)1099-1077(199701/02)12:1<41::aid-hup829>3.0.co;2-7


Related references

Double-blind randomized controlled study of the efficacy and tolerability of two reversible monoamine oxidase A inhibitors, pirlindole and moclobemide, in the treatment of depression. Acta Psychiatrica Scandinavica. 96(2): 134-141, 1997

A double-blind randomized placebo-controlled study of the efficacy and safety of pirlindole, a reversible monoamine oxidase A inhibitor, in the treatment of depression. Acta Psychiatrica Scandinavica 94(6): 404-410, 1996

Social phobia: the clinical efficacy and tolerability of the monoamine oxidase -A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study. Acta Psychiatrica Scandinavica 92(5): 351-358, 1995

Continuation and maintenance treatment of major depression with the monoamine oxidase inhibitor phenelzine: a double-blind placebo-controlled discontinuation study. Psychopharmacology Bulletin 27(1): 31-39, 1991

Oxcarbazepine--efficacy and tolerability during treatment of alcohol withdrawal: a double-blind, randomized, placebo-controlled multicenter pilot study. Alcoholism, Clinical and Experimental Research 31(7): 1188-1194, 2007

Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population. Journal of Clinical Psychopharmacology 30(4): 357-364, 2010

Efficacy of pirlindole, a highly selective reversible inhibitor of monoamine oxidase type A, in the prevention of experimentally induced epileptic seizures. Drug Investigation. 4(6): 501-507, 1992

A randomized, double-blind controlled comparison of nefazodone and paroxetine in the treatment of depression: safety, tolerability and efficacy in continuation phase treatment. Journal of Psychopharmacology 15(3): 161-165, 2001

Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration 2019: 1-8, 2019

Efficacy and tolerability of advanced glycation end-products inhibitor in osteoarthritis: a randomized, double-blind, placebo-controlled study. Clinical Journal of Pain 29(8): 717-724, 2014

Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: a randomized, placebo-controlled, double-blind, 12-week pilot study. Clinical Therapeutics 28(7): 1002-1011, 2006

Efficacy and tolerability of a spray formulation containing Visnadine in women self-reporting sexual symptoms: a randomized double-blind placebo-controlled pilot study. Journal of Endocrinological Investigation 41(6): 729-737, 2017

Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults A randomized, placebo-controlled, double-blind, 12-week pilot study vol 28, pg 1002, 2006. Clinical Therapeutics 28(9): 1482, 2000

Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. Journal of Psychiatric Research 46(1): 64-71, 2012

Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study. Alzheimer's Research and Therapy 10(1): 107, 2018